Introduction
Recent studies have shown that testosterone plays a major part in influencing bone mineral density. Increased bone fragility is a hallmark of osteoporosis, a condition caused by the destruction of bone microarchitecture and a reduction in bone density. One of the main causes of fractures in the vertebrae in middle-aged and older adults is osteoporosis, which has a significant negative impact on patient's quality of life and raises the socioeconomic burden on society. Clinical evidence indicates that testosterone supplements can increase bone mineral density in osteoporosis patients.
What Is Testosterone?
The principal male hormone in charge of controlling sex differentiation, generating traits exclusive to men, spermatogenesis, and fertility is testosterone. The development of basic sexual development, including spermatogenesis, testicular descent, penile and testicular growth, and increased sexual desire, is attributed to testosterone. In addition, testosterone has a role in controlling the traits that define masculinity or secondary male features. Male hair patterns, vocal alterations, voice deepening, puberty growth spurts, and skeletal muscle growth are examples of these secondary sex traits.
What Is Osteoporosis?
Osteoporosis develops when there is a decrease in bone mass and mineral density or when changes take place to the structure and makeup of bone. This condition often starts to manifest a year or two before menopause in females. Excessive loss of bone mass combined with structural alterations in bone tissue results in osteoporosis.
What Is Meant by Testosterone Therapy?
Male patients with low testosterone levels, or hypogonadism, are usually offered testosterone therapy, also known as testosterone replacement therapy (TRT).
In order to raise the level of the hormone in the body, testosterone is administered as part of the therapy. This can have a number of positive effects on the body, including higher libido, better sexual function, improved mood, enhanced well-being, and increased bone and muscular density.
How Testosterone Therapy Is Related to Osteoporosis and Bone Density?
Bone health is significantly impacted by testosterone. Research has demonstrated a link between osteoporosis and reduced testosterone levels. On the other hand, elevated testosterone levels, especially when they reach 500 ng/dL, have been linked to a negative effect on bone health. There seems to be a complex link between testosterone and bone mineral density (BMD) that varies depending on one's gender and race.
In men, there is a strong relationship between serum testosterone levels and BMD. Furthermore, androgen deprivation therapy for prostate cancer causes an instant drop in testosterone levels, which lowers osteoporosis and BMD. Furthermore, the preservation of BMD is closely linked to the conversion of testosterone by aromatase into estradiol (E2). Another risk factor for BMD loss is a relative drop in estrogen levels brought on by ADT. Generally speaking, BMD drops by between two and eight percent within a year after starting androgen deprivation therapy. Moreover, compared to individuals with prostate cancer and normal testosterone levels, androgen deprivation therapy patients have a five-to ten-fold increased risk of reduced BMD.
What Is the Impact of Testosterone Therapy on Bone Density and Bone Mass Loss?
-
Impact on the Density of Bones - By altering indicators associated with bone remodeling, testosterone therapy affects bone density. It might result in a long-term decrease in bone resorption and a transient boost in bone growth. This does not, however, automatically equate to a greater BMD. Within one to three months of starting treatment, testosterone therapy was shown to reduce markers of bone resorption, such as tartrate-resistant acid phosphatase and C-terminal telopeptide, in clinical trials. Osteocalcin and procollagen type 1 N-terminal propeptide are two examples of bone development markers that may rise initially before stabilizing after a year.
-
Possibility of Preventing or Reversing Bone Loss - Treatment with testosterone has been demonstrated to inhibit bone remodeling, although it has not always been linked to increased bone mineral density or a lower risk of fractures. In certain populations, such as obese men losing weight, testosterone may have a greater effect on bone mass loss since it can prevent diet-related muscle loss and maintain bone health.
One study discovered that testosterone therapy stopped obese hypogonadal men from losing bone when they were following a very low-calorie diet. After replacing the testosterone to normal levels, the BMD of the hips and spine was higher in the testosterone group than in the placebo group. This suggests that testosterone may be able to decrease bone loss in obese men who are trying to lose weight. More studies involving various populations are required.
What Other Factors Should Be Considered While Undergoing Testosterone Therapy for Osteoporosis?
The monitoring of testosterone therapy's effects on bone health depends heavily on bone mineral density scans. They support the evaluation of fracture risk and changes in bone density as well as osteoporosis. It is advised by guidelines to obtain a baseline DXA scan (dual X-ray absorptiometry scans) prior to beginning testosterone therapy. Biannual or yearly follow-up scans can track BMD alterations brought on by treatment. Strong bones can be maintained by eating a diet rich in calcium and vitamin D. Research on how testosterone therapy and deficiency of vitamin D interact to treat osteoporosis is still ongoing, although there may be positive combination effects on bone health.
Is Testosterone Therapy Safe to Take for Osteoporosis?
Like other drugs, there are advantages and disadvantages to testosterone therapy. The degree of risk varies from person to person and is influenced by factors like age, weight, health, and family history. To determine whether testosterone therapy is the best course of action for a person, it is critical to weigh each person's risks and advantages, as well as the best type to use and duration of treatment.
Conclusion
Bone health and testosterone therapy have a complicated relationship. Although it may help some people (such as hypogonadal males), the general efficacy of treating osteoporosis and boosting bone density is debatable. A crucial component of testosterone therapy in relation to bone health is monitoring and control using BMD scans and taking vitamin D levels into account. To completely comprehend the long-term impact of testosterone on bone density and osteoporosis treatment, more research is required.
